Concomitantly, the use of a specific HAS2 inhibitor would induce a reduction of the stroma content by decreasing HA synthesis by CAFs (Fig. 7) further contibuting to tumour growth/aggressiveness wane. This evidence concerns the gene HAS2 and neoplasm.